Modern Understanding of Severe Bronchial Asthma
https://doi.org/10.20514/2226-6704-2021-12-2-113-122
Abstract
The review provides data on severe bronchial asthma. Frequent exacerbations of asthma significantly reduce the quality of life of patients, cause disability, disability and death. The heterogeneity of severe bronchial asthma fits into the concepts of phenotype and endotype, the identification of which in clinical practice has limitations, but is necessary for personalized therapy. Analysis of the literature reflecting experience in patient data management is needed to form holistic perceptions of severe bronchial asthma and develop ways to optimize therapy.
About the Authors
A. Yu. Kraposhina
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Regional Government-Owned Publicly Funded Healthcare Institution “Regional Clinical Hospital”
Russian Federation
Competing Interests:
Russian Federation
Krasnoyarsk
Competing Interests:
The authors declare no conflict of interests
E. A. Sobko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Regional Government-Owned Publicly Funded Healthcare Institution “Regional Clinical Hospital”
Russian Federation
Competing Interests:
Russian Federation
Krasnoyarsk
Competing Interests:
The authors declare no conflict of interests
I. V. Demko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Regional Government-Owned Publicly Funded Healthcare Institution “Regional Clinical Hospital”
Russian Federation
Competing Interests:
Russian Federation
Krasnoyarsk
Competing Interests:
The authors declare no conflict of interests
A. B. Katser
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Krasnoyarsk
Competing Interests:
The authors declare no conflict of interests
O. V. Kazmerchuk
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Krasnoyarsk
Competing Interests:
The authors declare no conflict of interests
Yu. I. Abramov
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Krasnoyarsk
Competing Interests:
The authors declare no conflict of interests
References
1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Members of GINA Committees. 2020; 1-211. [Electronic resource]. URL: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.
2. Avdeev S.N., Nenasheva N.M., Zhudenkov K.V. et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Russian Pulmonology. 2018; 28(3): 341-358. doi: 10.18093/0869-0189-2018-28-3-341-358 [In Russian].
3. Demko I.V., Sobko E.A., Chubarova S.V. et al. Features of the systemic inflammation, external respiration functions and morphological structure of the bronchial mucous membrane in severe bronchial asthma. Sibirskoe meditsinskoe obozrenie. 2014; 5: 47-52. [In Russian].
4. Belevsky A.S., Zaitsev A.A. Pharmacoeconomic aspects of bronchial asthma therapy: real clinical practice. Meditsinskiy sovet = Medical Council. 2018; (15): 60-68. doi: 10.21518/2079-701X-2018-15-60-68 [In Russian].
5. Nagase H. Severe asthma in Japan. Allergology International. 2019; 68(2): 167-171. doi:10.1016/j.alit.2019.02.004
6. O’Toole J., Mikulic L., Kaminsky D.A. Epidemiology and pulmonary physiology of severe asthma. Immunology and Allergy Clinics of North America. 2016; 36(3): 425-438. doi: 10.1016/j.iac.2016.03.001
7. Brodskaya O.N. Bronchial asthma with frequent exacerbations: risk factors and prevention measures. Prakticheskaya pul’monologiya. 2016; 3: 11-18. [In Russian].
8. Zein J.G., Dweik R.A., Comhair S.A. et al. Asthma is more severe in older adults. PLoS One. 2015; 10(7): e0133490. doi: 10.1371/journal. pone.0133490
9. Nenasheva NM. This is a difficult word for «compliance», or How one can increase adherence to treatment for bronchial asthma. Asthma and allergy. 2013:2:15-19. [In Russian].
10. Hekking P.W., Wener R.R., Amelink M. et al. The prevalence of severe refractory asthma. Journal of Allergy and Clinical Immunology. 2015; 135(4): 896-902. doi: 10.1016/j.jaci.2014.08.042
11. von Bülow A., Backer V., Bodtger U. et al. Differentiation of adult severe asthma from difficult-to-treat asthma — Outcomes of a systematic assessment protocol. Respiratory Medicine. 2018; 145: 41-47. doi: 10.1016/j.rmed.2018.10.020
12. van der Meer A.N., Pasma H., Kempenaar-Okkema W. et al. A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use. European Respiratory Journal. 2016; 48(3): 726-733. doi: 10.1183/13993003.00220-2016
13. Verhamme K.M.C., Lucet C., Van Meerhaeghe A. et al. Real- life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. European Journal of Operational Research. 2019; 5: 00253-2018. doi: 10.1183/23120541.00253-2018
14. Chung K.F., Wenzel S.E., Brozek J.L. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal. 2014; 43(2): 343-373. doi: 10.1183/09031936.00202013
15. Wark P.A.B, Hew M., Maltby S. et al. Diagnosis and investigation in the severe asthma clinic. Expert review of respiratory medicine. 2016; 10(5): 491-503. doi: 10.1586/17476348.2016.1165096
16. Majellano E.C., Clark V.L., Winter N.A. et al. Approaches to the assessment of severe asthma: barriers and strategies. Journal of Asthma and Allergy. 2019; 12: 235-251 doi: 10.2147/JAA.S178927
17. Hashimoto S., Bel E.H. Current treatment of severe asthma. Clinical and Experimental Allergy. 2012; 42(5): 693-705. doi: 10.1111/j.1365- 2222.2011.03936.x
18. Jeong J.S., Lee Y.C. Basics of Severe Asthma in Clinical Practice. In: Severe Asthma. Springer, Singapore. 2018: 3-12. doi: 10.1007/978- 981-10-1998-2_1
19. Kang H-R., Song H.J., Nam J.H. et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population- based observational study in South Korea. BMJ Open. 2018; 8(3): e020825. doi: 10.1136/bmjopen-2017-020825
20. McDonald V.M., Maltby S., Reddel H.K. et al. Severe asthma: Current management, targeted therapies and future directions-A roundtable report. Respirology. 2017; 22(1): 53-60. doi: 10.1111/resp.12957
21. Menzies-Gow A., Chiu G. Perceptions of asthma control in the United Kingdom: a cross-sectional study comparing patient and healthcare professionals’ perceptions of asthma control with validated ACT scores. NPJ Primary Care Respiratory Medicine. 2017; 27(1): 48. doi: 10.1038/s41533-017-0050-x
22. Burke H., Davis J., Evans S. et al. A multidisciplinary team case management approach reduces the burden of frequent asthma admissions. European Journal of Operational Research. 2016; 2(3): 00039-2016. doi: 10.1183/23120541.00039-2016
23. Hedenrud T., Jakobsson A., Malla H.E., et al. «I did not know it was so important to take it the whole time» — self-reported barriers to medical treatment among individuals with asthma. BMC Pulmonary Medicine. 2019; 19: 175. doi: 10.1186/s12890-019-0934-3
24. Gregoriano C., Dieterle T., Breitenstein A. et al. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial. Respiratory Research. 2018; 19(1): 237. doi: 10.1186/s12931-018-0936-3
25. Lavorini F., Usmani O. Correct inhalation technique is critical in achieving good asthma control. Primary Care Respiratory Journal. 2013; 22: 385-386. doi: 10.4104/pcrj.2013.00097
26. Jahedi L., Downie S.R., Saini B. et al. Inhaler Technique in Asthma: How Does It Relate to Patients’ Preferences and Attitudes Toward Their Inhalers? Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2017; 30(1): 42-52. doi: 10.1089/jamp.2016.1287
27. Asano K., Izuhara K. What we know, do not know, and should know about severe asthma. Allergology International. 2019; 68(2): 133-134. doi: 10.1016/j.alit.2019.03.002
28. Nenasheva NM. Phenotypes and choice of therapy. Prakticheskaya pul’monologiya. 2014; 2: 2-11. [In Russian].
29. Clinical guidelines. Bronchial asthma. Ministry of Health of the Russian Federation. 2021; 1-85. [Electronic resource]. URL: http://disuria.ru/_ld/10/1037_kr21J45J46MZ.pdf (date accessed 23/06/2021). [In Russian]
30. Sergeeva G.R., Emelyanov A.V., Korovina O.V. et al. Severe asthma: Characteristics of patients in clinical practice. Terapevticheskii arkhiv. 2015; 87(12): 26-31. [In Russian].
31. Nenasheva N.M., Belevskiy A.S., Fassahov R.S. et al. Asthma phenotypes difficult to treat: the possibility to achive a control. Russian Journal of Allergy. 2016; 4-5:43-54. [In Russian].
32. Kämpe M., Vosough M, Malinovschi A. et al. Upper airway and skin symptoms in allergic and non-allergic asthma: results from the Swedish GA2LEN study. Journal of Asthma. 2018; 55(3): 275-283. doi: 10.1080/02770903.2017.1326132
33. Hirano T., Matsunaga K. Late-onset asthma: current perspectives. Journal of Asthma and Allergy. 2018 Feb 9; 11:19-27. Doi: 10.2147/JAA.S125948
34. Tan D.J., Walters E.H., Perret J.L. et al. Clinical and functional differences between early-onset and late-onset adult asthma: a population-based Tasmanian Longitudinal Health Study. Thorax. 2016; 71(11): 981–987. doi: 10.1136/thoraxjnl-2015-208183
35. Konstantellou E., Papaioannou A.I., Loukides S. et al. Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype. Respiratory Medicine. 2015; 109: 1404-1409. doi: 10.1016/j.rmed.2015.09.009
36. Ciebiada M., Domagała M., Gorska-Ciebiada M., et al. Risk factors associated with irreversible airway obstruction in nonsmoking adult patients with severe asthma. Allergy and Asthma Proceedings. 2014; 35(5): 72-79. doi: 10.2500/aap.2014.35.3785
37. Bennett G.H., Carpenter L., Hao W. et al. Risk factors and clinical outcomes associated with fixed airflow obstruction in older adults with asthma. Annals of Allergy, Asthma and Immunology. 2018; 120(2): 164-168. doi: 10.1016/j.anai.2017.10.004
38. Wang L., Gao S., Zhu W. et al. Risk factors for persistent airflow limitation: analysis of 306 patients with asthma. Pakistan Journal of Medical Sciences. 2014; 30(6): 1393-1397. doi: 10.12669/pjms.306.5363
39. Haddad A., Gaudet M., Plesa M. et al. Neutrophils from severe asthmatic patients induce epithelial to mesenchymal transition in healthy bronchial epithelial cells. Respiratory Research. 2019; 20(1): 234. doi: 10.1186/s12931-019-1186-8
40. Tashiro H., Shore S.A. Obesity and severe asthma. Allergology International. 2019; 68(2): 135-142. doi:10.1016/j.alit.2018.10.004.
41. Kim S., Lee C.H., Jin K.N. et al. Severe Asthma Phenotypes Classified by Site of Airway Involvement and Remodeling via Chest CT scan. J Investig Allergol Clin Immunol. 2018; 28(5): 312-320. doi: 10.18176/jiaci.0265.
42. Robinson D., Humbert M., Buhl R. et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical and Experimental Allergy. 2017; 47(2): 161–175. doi: 10.1111/cea.12880.
43. Kuruvilla M.E., Lee F.E-H., Lee G.B. Understanding asthma Phenotypes, endotypes, and mechanisms of disease. Clinical Reviews in Allergy and Immunology. 2019; 56(2): 219–233. doi: 10.1007/s12016-018-8712-1
44. Sze E., Bhalla A., Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020; 75(2): 311–325. doi: 10.1111/all.13985
45. Mogensen I., Alving K., Dahlen S-E. Et al. Fixed airflow obstruction relates to eosinophil activation in asthmatics. Clinical and Experimental Allergy. 2019; 49: 155–162. doi: 10.1111/cea.13302
46. Prosekova E.V., Turyanskaya A.I., Dolgopolov M.S. Interleukin-17 family in atopy and allergic diseases. Pacific Medical Journal. 2018; 2: 15–20. doi: 10.17238/PmJ1609-1175.2018.2.15–20 [In Russian].
47. Tliba O., Panettieri R.A. Paucigranulocytic asthma: The uncoupling of airway obstruction from inflammation. Journal of Allergy and Clinical Immunology. 2019; 143(4): 1287–1294. doi: 10.1016/j.jaci.2018.06.008
48. Rogliani P., Calzetta L., Matera M.G. et al. Severe asthma and biological therapy: when, which, and for whom. Pulmonary Therapy. 2020; 6(1): 47–66. doi: 10.1007/s41030-019-00109-1
49. Pavord I.D., Afzalnia S., Menzies-Gow A., Heaney L.G. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clinical and Experimental Allergy. 2017; 47(2): 148-60. doi: 10.1111/cea.12881
Review
For citations:
Kraposhina A.Yu., Sobko E.A., Demko I.V., Katser A.B., Kazmerchuk O.V., Abramov Yu.I. Modern Understanding of Severe Bronchial Asthma. The Russian Archives of Internal Medicine. 2022;12(2):113-122. https://doi.org/10.20514/2226-6704-2021-12-2-113-122
Views:
939
Email this article 